XERS
Xeris Biopharma Holdings Inc

10,568
Mkt Cap
$1.18B
Volume
1.74M
52W High
$10.08
52W Low
$3.02
PE Ratio
-68.57
XERS Fundamentals
Price
$6.84
Prev Close
$7.09
Open
$7.25
50D MA
$8.31
Beta
1.38
Avg. Volume
2.2M
EPS (Annual)
-$0.3736
P/B
-1,363.46
Rev/Employee
$515,406.09
Loading...
Loading...
News
all
press releases
Xeris Biopharma (NASDAQ:XERS) Insider Sells $173,385.32 in Stock
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) insider John Patrick Shannon, Jr. sold 23,242 shares of Xeris Biopharma stock in a transaction on Thursday, November 13th. The shares...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Insider Selling: Xeris Biopharma (NASDAQ:XERS) Insider Sells 23,242 Shares of Stock
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) insider John Patrick Shannon, Jr. sold 23,242 shares of the business's stock in a transaction on Thursday, November 13th. The shares...
MarketBeat·3d ago
News Placeholder
Leerink Partnrs Forecasts Xeris Biopharma FY2025 Earnings
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) - Equities researchers at Leerink Partnrs increased their FY2025 earnings per share estimates for shares of Xeris Biopharma in a report...
MarketBeat·4d ago
News Placeholder
Campbell & CO Investment Adviser LLC Takes $618,000 Position in Xeris Biopharma Holdings, Inc. $XERS
Campbell & CO Investment Adviser LLC acquired a new position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) in the second quarter, according to its most recent disclosure...
MarketBeat·5d ago
News Placeholder
Xeris Biopharma (NASDAQ:XERS) Insider Sells $123,335.80 in Stock
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) insider Beth Hecht sold 16,667 shares of Xeris Biopharma stock in a transaction dated Tuesday, November 11th. The stock was sold at an...
MarketBeat·5d ago
News Placeholder
Analysts Set Expectations for Xeris Biopharma Q4 Earnings
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) - Investment analysts at Leerink Partnrs lifted their Q4 2025 earnings estimates for Xeris Biopharma in a research report issued to clients...
MarketBeat·5d ago
News Placeholder
Beth Hecht Sells 16,667 Shares of Xeris Biopharma (NASDAQ:XERS) Stock
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) insider Beth Hecht sold 16,667 shares of the business's stock in a transaction dated Tuesday, November 11th. The shares were sold at an...
MarketBeat·6d ago
News Placeholder
Wall Street Zen Downgrades Xeris Biopharma (NASDAQ:XERS) to Hold
Wall Street Zen downgraded shares of Xeris Biopharma from a "strong-buy" rating to a "hold" rating in a report on Saturday...
MarketBeat·13d ago
News Placeholder
Xeris Biopharma (NASDAQ:XERS) Shares Gap Down - Here's Why
Xeris Biopharma (NASDAQ:XERS) Shares Gap Down - Here's Why...
MarketBeat·13d ago
News Placeholder
Xeris Biopharma (XERS) Reports Q3 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Xeris Biopharma (XERS) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks·14d ago

Latest XERS News

View

Advertisement|Remove ads.

Advertisement|Remove ads.